JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)

Leukemia Research

Volumn 33, Issue 12, 2009, Pages

  Kodali, Srinivas ^a   Chen, Chi ^a   Rathnasabapathy, Chenthilmurugan ^a   Wang, Jen Chin ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia (CLL); JAK2 mutation; Myeloproliferative neoplasm (MPN)

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HYDROXYUREA; JANUS KINASE 2; PROTEIN KINASE ZAP 70;

AGED; B LYMPHOCYTE; BLOOD SMEAR; BONE MARROW BIOPSY; BONE MARROW CELL; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HETEROZYGOSITY; HUMAN; HUMAN CELL; LETTER; LEUKOCYTOSIS; LYMPHOCYTE COUNT; MEGAKARYOCYTE; MYELOPROLIFERATIVE DISORDER; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; MYELOPROLIFERATIVE DISORDERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 70249090706     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.027     Document Type: Letter

References (15)

1. Gabrail N.Y., and Martin T.W. Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. Acta Haematol 85 (1998) 31-33
2. Bizzara N. Chronic lymphocytic leukemia in a patient with essential thrombocythemia. Clin Lab Haematol 20 (1998) 377-379
3. Robak T., Urbanska-Rys H., Gora-Tybor J., et al. Coexistence of chronic lymphocytic leukemia and essential thrombocythemia. Leuk Lymphoma 44 (2003) 1425-1431
4. Henry L., Carillo S., Jourdan E., Arnaud A., Brun S., and Lavabre-Bertrand T. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol 82 (2007) 500-501
5. Zap-70 positive chronic lymphocytic leukemia co-existing with JAK 2 V671F positive essential thrombocythemia: a common defective stem cell?. Leuk Res (2008) [Epub ahead of print, October 10]
6. Wendy H., Raskind, and Flaikow P.J. The use of cell markers in the study of human hematopoetic neoplasia. Adv Cancer Res 49 (1987) 127-167
7. Levine R.L., Loriaux M.J.P., Huntly B., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106 (2005) 3377-3379
8. Poulain S., Merchez M., Daudignon A., Simon M., Duthilleul P., and Morel P. JAK2 V617F mutation is absent in chronic lymphocytic leukemia. Leuk Lymphoma 47 December (12) (2006) 2657-2658
9. Tiedt R., Hao-Shen H., Sobas M.A., et al. Ratio of mutant Jak2-V617F to wild type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111 (2008) 3931-3940
10. Zehentner B.K., Loken M.R., and Wells D.A. Jak2 mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders. Am J Hematol 81 (2006) 806-807
11. Ishii T. Involvement of various hematopoetic cell lineages by JAK2 V617F mutation in polycythemia vera. Blood 108 (2006) 3128-3134
12. Hussein K., Brakensiek K., Ballmaier M., et al. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol 77 December (6) (2006) 539-541
13. James C., Ugo V., Le Couédic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434 April (7037) (2005) 1144-1148
14. Guerriero R., Testa U., Gabbianelli M., et al. Unilineage megakaryocytic proliferation and differentiation of purified hematopoietic progenitors in serum-free liquid culture. Blood 86 (1995) 3725-3736
15. Baxter E.J., Scott L.M., Campbell P.J., et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 366 9480 (2005) 122